Cannabics Pharmaceuticals Inc (OTCMKTS:CNBX) is a stock that’s been advancing nicely helped along by recent news out of the company, including the announcement that results from the company’s Cancer HTS research indicates that specific ratios of Cannabinoids led to Apoptosis in MDA-MB-231 Breast Cancer cell viability. The news has spurred a bounce following a sharp fade in the wake of the key November 8 voting result in eight US states.
Traders will note 36% piled on for shareholders of the company during the trailing week. CNBX is a stock whose past is littered with sudden rips and sharp rallies. Moreover, the listing has benefitted from a jump in recent trading volume to the tune of approaching 220% beyond what we have been seeing over the larger time frame. Traders should note this as important due to the limited float size in the stock (not even 15M shares). It’s something the veterans know to key on: a mechanically driven price squeeze can result from this type of mix of small float and ramping attention from traders.
Cannabics Pharmaceuticals Inc (OTCMKTS:CNBX) promulgates itself as a company that engages in the research, development, licensing, and marketing of cannabinoid-based treatments and therapies. The company focuses on developing therapies and biotechnological tools for the relief from various ailments that respond to active ingredients sourced from the cannabis plant.
Its flagship product is Cannabics SR, a long-acting medical cannabis capsule that shows therapeutic effects as a palliative care therapy for cancer patients.
The Company’s R&D is based in Israel, where it is licensed by the Ministry of Health for its work in both scientific and academic research as well as current clinical studies underway at Rambam Hospital.
The Company’s scientific focus is on identifying and harnessing the therapeutic properties of specific natural Cannabinoids. Cannabics’ vision is to create individually tailored therapies for cancer patients, utilizing advanced screening systems and personalized bioinformatics tools.
The company was formerly known as American Mining Corporation and changed its name to Cannabics Pharmaceuticals Inc. in May 2014. Cannabics Pharmaceuticals Inc. is based in Bethesda, Maryland. As of April 25, 2014, Cannabics Pharmaceuticals Inc. operates as a subsidiary of Cannabics Inc.
Find out when $CNBX stock reaches critical levels. Subscribe to OracleDispatch.com Right Now by entering your Email in the box below.
As noted above, Cannabics Pharmaceuticals is currently developing a personalized treatment based upon screening of patients’ biopsy and delivering specified cannabinoid medicine which contains anti-tumor properties.
The company is moving on the belief that this technology will enable oncologist and other treating physicians to provide cancer patients with a personalized anti-cancer cannabinoid-based therapy.
“We are building a database of patients and compounds, the screening data and the clinical efficacy will be centralized and in proprietary software,” said Itamar Borochov, CEO of Cannabics Pharmaceuticals Inc. “Results from the screening of numerous cancer types will produce new data and new patent applications of compounds with anti-cancer properties.”
“Results from the screening of numerous cancer types will produce new data and new patent applications of compounds with anti-cancer properties.”
According to the company’s chief scientist, one should understand the Cannabics’ method of diagnosis as clearly differentiating between a multitude of varied plant extracts and their apoptotic and necrotic effects by utilizing state of the art HTS (High Throughput Screening) on cells derived from patients’ biopsies; the results of which are visualized in “scans” of the before, during and after effect upon the cancer cells themselves.
“When cross-linked with patients’ medical database and proprietary plant extracts, patients may receive a personalized anticancer therapy combined with the palliative effect of cannabis.”
“We are pioneers in the recruitment of HTS technology to evaluate the anti-cancer properties of cannabinoid compounds through the assessment of their observed biological activity on cancer cell lines and patients’ tumor cells. We are also actively developing proprietary and novel compounds specifically targeted on diverse types of tumors. These compounds will be further examined in controlled clinical studies in Israel and finally it is expected through the US FDA.”
Earning a current market cap value of $92M, CNBX has almost no cash on the books, alongside total assets of $93K, which must be weighed relative to de minimus total accumulated debt.
CNBX is making some money, with trailing 12-month revenues coming in at 62.50k. But the top line is not growing yet. However, with promising projects already underway and a lack of debt, this stock has a little leeway and a strong context for future operations. We will update the story again soon as further details emerge. For continuing coverage on shares of $CNBX stock, as well as our other hot stock picks, sign up for our free newsletter today and get our next hot stock pick!